Lord, Abbett & Co’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-73,020
| Closed | -$6.03M | – | 595 |
|
|
2022
Q3 | $6.03M | Sell |
73,020
-1,300,714
| -95% | -$125M | 0.02% | 457 |
|
|
2022
Q2 | $131M | Buy |
1,373,734
+60,686
| +5% | +$6.28M | 0.46% | 47 |
|
|
2022
Q1 | $155M | Buy |
1,313,048
+419,157
| +47% | +$47M | 0.41% | 58 |
|
|
2021
Q4 | $116M | Sell |
893,891
-684,749
| -43% | -$79.9M | 0.26% | 115 |
|
|
2021
Q3 | $179M | Buy |
1,578,640
+996,051
| +171% | +$114M | 0.43% | 50 |
|
|
2021
Q2 | $60.3M | Buy |
+582,589
| New | +$54.9M | 0.15% | 218 |
|
|
2020
Q1 | – | Sell |
-267,693
| Closed | -$20.8M | – | 655 |
|
|
2019
Q4 | $20.8M | Sell |
267,693
-235,107
| -47% | -$18.4M | 0.07% | 380 |
|
|
2019
Q3 | $36.9M | Buy |
502,800
+445,557
| +778% | +$31.3M | 0.13% | 278 |
|
|
2019
Q2 | $3.52M | Sell |
57,243
-470,448
| -89% | -$28.4M | 0.01% | 678 |
|
|
2019
Q1 | $33.7M | Sell |
527,691
-291,579
| -36% | -$16.6M | 0.11% | 294 |
|
|
2018
Q4 | $41.8M | Buy |
819,270
+512,706
| +167% | +$25.9M | 0.15% | 211 |
|
|
2018
Q3 | $17.8M | Sell |
306,564
-489,117
| -61% | -$23.9M | 0.05% | 502 |
|
|
2018
Q2 | $38.6M | Buy |
795,681
+456,486
| +135% | +$21.3M | 0.11% | 290 |
|
|
2018
Q1 | $15.8M | Buy |
339,195
+83,001
| +32% | +$3.6M | 0.05% | 522 |
|
|
2017
Q4 | $9.63M | Buy |
256,194
+38,772
| +18% | +$1.42M | 0.03% | 625 |
|
|
2017
Q3 | $7.92M | Sell |
217,422
-33,732
| -13% | -$1.29M | 0.02% | 674 |
|
|
2017
Q2 | $9.9M | Buy |
251,154
+92,625
| +58% | +$3.38M | 0.03% | 633 |
|
|
2017
Q1 | $4.97M | Sell |
158,529
-70,893
| -31% | -$2.22M | 0.01% | 745 |
|
|
2016
Q4 | $7.17M | Sell |
229,422
-1,492,329
| -87% | -$48.4M | 0.02% | 656 |
|
|
2016
Q3 | $69.2M | Buy |
1,721,751
+226,146
| +15% | +$8.52M | 0.21% | 141 |
|
|
2016
Q2 | $49.7M | Sell |
1,495,605
-713,817
| -32% | -$24.4M | 0.16% | 204 |
|
|
2016
Q1 | $65M | Buy |
2,209,422
+253,329
| +13% | +$6.99M | 0.2% | 149 |
|
|
2015
Q4 | $51.5M | Buy |
1,956,093
+171,009
| +10% | +$4.44M | 0.15% | 192 |
|
|
2015
Q3 | $42.3M | Buy |
1,785,084
+296,550
| +20% | +$7.16M | 0.13% | 254 |
|
|
2015
Q2 | $35.3M | Buy |
1,488,534
+28,782
| +2% | +$650K | 0.09% | 345 |
|
|
2015
Q1 | $34.7M | Buy |
1,459,752
+916,356
| +169% | +$20.6M | 0.09% | 353 |
|
|
2014
Q4 | $11.5M | Sell |
543,396
-272,148
| -33% | -$5.47M | 0.03% | 584 |
|
|
2014
Q3 | $13.9M | Buy |
+815,544
| New | +$12.9M | 0.03% | 553 |
|
Other funds holding EW
Lord, Abbett & Co's EW Position: Q4 2022 in Review
Lord, Abbett & Co sold out of Edwards Lifesciences (EW) in Q4 2022, closing a stake of 73,020 shares — an estimated $6.03M sold.
Lord, Abbett & Co first reported a position in EW in Q3 2014 and held it in 28 quarters. The position peaked at $179M in Q3 2021. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2022.
- Lord, Abbett & Co reported no remaining Edwards Lifesciences position as of Q4 2022 after selling out during the quarter.
- Lord, Abbett & Co sold 73,020 Edwards Lifesciences shares in Q4 2022, an estimated $6.03M.
- Lord, Abbett & Co first reported a position in Edwards Lifesciences in Q3 2014 and held it in 28 quarters.
- Lord, Abbett & Co's Edwards Lifesciences position peaked at $179M in Q3 2021.
- 1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2022.
Based on Lord, Abbett & Co's 13F filing for Q4 2022, filed 10 Feb 2023.